Tirzepatide, also known as Mounjaro, Zepbound, and LY3298176, is a novel synthetic peptide-based compound developed by Eli Lilly and Company. It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The compound is synthesized through recombinant DNA technology, resulting in a molecule that combines the properties of both incretin hormones. Tirzepatide is designed to mimic the natural incretin hormones that play a role in glucose regulation and energy balance. Researchers have primarily investigated tirzepatide in the context of metabolic disorders, including type 2 diabetes and obesity. Clinical trials have demonstrated its efficacy in improving glycemic control and promoting weight loss in patients with type 2 diabetes. Additionally, studies have shown that tirzepatide can reduce cardiovascular risk factors, such as blood pressure and lipid levels. The mechanism of action of tirzepatide involves the activation of both GIP and GLP-1 receptors. This dual agonism enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to improved glucose homeostasis and reduced appetite. The pharmacokinetic profile of tirzepatide reveals a half-life of approximately 5 days when administered subcutaneously, allowing for once-weekly dosing. It exhibits high stability and bioavailability when delivered via this route. Current research on tirzepatide is focused on its long-term effects and potential applications in other metabolic conditions. It has received regulatory approval for the treatment of type 2 diabetes in several countries, with ongoing studies exploring its use in obesity management. The compound is not yet approved for use in all regions, and its regulatory status may vary globally.